vs
Side-by-side financial comparison of MEDIFAST INC (MED) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $75.1M, roughly 1.0× MEDIFAST INC). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -36.9%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $-6.6M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs -34.4%).
Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
MED vs PBYI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.1M | $75.5M |
| Net Profit | — | — |
| Gross Margin | 69.4% | 69.3% |
| Operating Margin | -10.4% | 22.7% |
| Net Margin | — | — |
| Revenue YoY | -36.9% | 27.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-1.64 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.1M | $75.5M | ||
| Q3 25 | $89.4M | $54.5M | ||
| Q2 25 | $105.6M | $52.4M | ||
| Q1 25 | $115.7M | $46.0M | ||
| Q4 24 | $119.0M | $59.1M | ||
| Q3 24 | $140.2M | $80.5M | ||
| Q2 24 | $168.6M | $47.1M | ||
| Q1 24 | $174.7M | $43.8M |
| Q4 25 | — | — | ||
| Q3 25 | $-2.3M | $8.8M | ||
| Q2 25 | $2.5M | $5.9M | ||
| Q1 25 | $-772.0K | $3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.1M | $20.3M | ||
| Q2 24 | $-8.2M | $-4.5M | ||
| Q1 24 | $8.3M | $-4.8M |
| Q4 25 | 69.4% | 69.3% | ||
| Q3 25 | 69.5% | 77.7% | ||
| Q2 25 | 72.6% | 76.5% | ||
| Q1 25 | 72.8% | 77.1% | ||
| Q4 24 | 74.1% | 76.4% | ||
| Q3 24 | 75.4% | 63.9% | ||
| Q2 24 | 73.2% | 77.4% | ||
| Q1 24 | 72.8% | 75.5% |
| Q4 25 | -10.4% | 22.7% | ||
| Q3 25 | -4.6% | 17.6% | ||
| Q2 25 | -1.0% | 12.7% | ||
| Q1 25 | -1.1% | 8.7% | ||
| Q4 24 | 0.6% | 22.6% | ||
| Q3 24 | 1.5% | 27.4% | ||
| Q2 24 | -4.7% | -4.6% | ||
| Q1 24 | 4.5% | -5.3% |
| Q4 25 | — | — | ||
| Q3 25 | -2.5% | 16.2% | ||
| Q2 25 | 2.3% | 11.2% | ||
| Q1 25 | -0.7% | 6.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.8% | 25.2% | ||
| Q2 24 | -4.8% | -9.6% | ||
| Q1 24 | 4.8% | -11.0% |
| Q4 25 | $-1.64 | $0.26 | ||
| Q3 25 | $-0.21 | $0.17 | ||
| Q2 25 | $0.22 | $0.12 | ||
| Q1 25 | $-0.07 | $0.06 | ||
| Q4 24 | $0.08 | $0.40 | ||
| Q3 24 | $0.10 | $0.41 | ||
| Q2 24 | $-0.75 | $-0.09 | ||
| Q1 24 | $0.76 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.3M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $198.9M | $130.3M |
| Total Assets | $248.0M | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.3M | $97.5M | ||
| Q3 25 | $173.5M | $94.4M | ||
| Q2 25 | $162.7M | $96.0M | ||
| Q1 25 | $164.6M | $93.2M | ||
| Q4 24 | $162.3M | $101.0M | ||
| Q3 24 | $170.0M | $96.7M | ||
| Q2 24 | $163.5M | $96.8M | ||
| Q1 24 | $156.4M | $107.2M |
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
| Q4 25 | $198.9M | $130.3M | ||
| Q3 25 | $214.7M | $115.3M | ||
| Q2 25 | $216.0M | $104.7M | ||
| Q1 25 | $211.0M | $97.1M | ||
| Q4 24 | $210.1M | $92.1M | ||
| Q3 24 | $207.3M | $71.1M | ||
| Q2 24 | $205.3M | $48.5M | ||
| Q1 24 | $211.0M | $51.0M |
| Q4 25 | $248.0M | $216.3M | ||
| Q3 25 | $268.2M | $202.9M | ||
| Q2 25 | $269.3M | $194.9M | ||
| Q1 25 | $280.0M | $196.2M | ||
| Q4 24 | $284.2M | $213.3M | ||
| Q3 24 | $291.2M | $220.7M | ||
| Q2 24 | $293.5M | $205.0M | ||
| Q1 24 | $302.8M | $214.1M |
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.3M | $14.4M |
| Free Cash FlowOCF − Capex | $-6.6M | $14.4M |
| FCF MarginFCF / Revenue | -8.8% | 19.1% |
| Capex IntensityCapex / Revenue | 1.8% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.2M | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.3M | $14.4M | ||
| Q3 25 | $12.1M | $9.7M | ||
| Q2 25 | $-3.4M | $14.1M | ||
| Q1 25 | $3.4M | $3.6M | ||
| Q4 24 | $-4.9M | $15.6M | ||
| Q3 24 | $9.1M | $11.0M | ||
| Q2 24 | $13.1M | $1.0M | ||
| Q1 24 | $7.3M | $11.2M |
| Q4 25 | $-6.6M | $14.4M | ||
| Q3 25 | $10.8M | $9.7M | ||
| Q2 25 | $-4.8M | $14.1M | ||
| Q1 25 | $1.9M | $3.6M | ||
| Q4 24 | $-7.2M | $15.6M | ||
| Q3 24 | $7.7M | $11.0M | ||
| Q2 24 | $11.1M | $1.0M | ||
| Q1 24 | $5.4M | — |
| Q4 25 | -8.8% | 19.1% | ||
| Q3 25 | 12.0% | 17.7% | ||
| Q2 25 | -4.5% | 26.8% | ||
| Q1 25 | 1.6% | 7.7% | ||
| Q4 24 | -6.1% | 26.4% | ||
| Q3 24 | 5.5% | 13.7% | ||
| Q2 24 | 6.6% | 2.1% | ||
| Q1 24 | 3.1% | — |
| Q4 25 | 1.8% | 0.0% | ||
| Q3 25 | 1.5% | 0.0% | ||
| Q2 25 | 1.3% | 0.0% | ||
| Q1 25 | 1.3% | 0.1% | ||
| Q4 24 | 1.9% | 0.0% | ||
| Q3 24 | 1.0% | 0.0% | ||
| Q2 24 | 1.1% | 0.0% | ||
| Q1 24 | 1.1% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | -1.36× | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.04× | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
